NCT/Study#

NCT04016805 /

UTX-TGR-208

A Phase 2 Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects with Chronic Lymphocytic Leukemia (CLL) Currently Treated with Ibrutinib or Venetoclax

A Phase 2 Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects with Chronic Lymphocytic Leukemia (CLL) Currently Treated with Ibrutinib or Venetoclax

DISEASE GROUP:
Lymphoma
current phase:
Phase II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: